Mark F Dalton Net Worth

The estimated Net Worth of Mark F Dalton is at least $322 mil dollars as of 14 May 2008. Mark Dalton owns over 7,500 units of Progenics Pharmaceuticals stock worth over $321,850 and over the last 22 years Mark sold PGNX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mark Dalton PGNX stock SEC Form 4 insiders trading

Mark has made over 1 trades of the Progenics Pharmaceuticals stock since 2008, according to the Form 4 filled with the SEC. Most recently Mark exercised 7,500 units of PGNX stock worth $40,200 on 14 May 2008.

The largest trade Mark's ever made was exercising 7,500 units of Progenics Pharmaceuticals stock on 14 May 2008 worth over $40,200. On average, Mark trades about 750 units every 0 days since 2003. As of 14 May 2008 Mark still owns at least 78,500 units of Progenics Pharmaceuticals stock.

You can see the complete history of Mark Dalton stock trades at the bottom of the page.

What's Mark Dalton's mailing address?

Mark's mailing address filed with the SEC is 1275 KING STREET, , GREENWICH, CT, 06831.

Insiders trading at Progenics Pharmaceuticals

Over the last 22 years, insiders at Progenics Pharmaceuticals have traded over $11,559,939 worth of Progenics Pharmaceuticals stock and bought 2,672,016 units worth $11,900,148 . The most active insiders traders include Healthcare Master Fund Ltd ..., Michael D Kishbauch, eBradley L Campbell. On average, Progenics Pharmaceuticals executives and independent directors trade stock every 16 days with the average trade being worth of $60,241. The most recent stock trade was executed by Capital, L.P.Altiva Managem... on 9 September 2019, trading 72,023 units of PGNX stock currently worth $359,395.

What does Progenics Pharmaceuticals do?

Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon in 1986 and is headquartered in New York, NY.

Complete history of Mark Dalton stock trades at Progenics Pharmaceuticals

Progenics Pharmaceuticals executives and stock owners

Progenics Pharmaceuticals executives and other stock owners filed with the SEC include:

• Partners, Llc Melkonian Cap...,
  
• Nicole Williams,
  Director
• Healthcare Master Fund Ltd ...,
  
• Healthcare Master Fund Ltd ...,
  
• Sheldon Hirt,
  Executive VP & General Counsel
• Michael D Kishbauch,
  Director
• David A Scheinberg,
  Director
• Karen Jean Ferrante,
  Director
• Peter J Crowley,
  Director
• Bradley L Campbell,
  Director
• Jeffery Summer,
  SVP, Digital Technology
• Patrick Fabbio,
  CFO
• Mark Robert Baker,
  CEO
• Charles A Baker,
  Director
• Kurt W Briner,
  Director
• Stephen P Goff,
  Director
• Mark F Dalton,
  Director
• Thomas A Boyd,
  SR. VP, Product Development
• Paul F Jacobson,
  Director
• Robert A Mckinney,
  VP of Finance and Admin
• Alton B Kremer,
  VP, Clinical Research
• Robert J Israel,
  Senior VP Medical Affairs
• Philip K Yachmetz,
  VP, Gen Counsel and Secretary
• Ronald J Prentki,
  President
• William C Olson,
  Senior VP, Research and Develo
• Paul J Maddon,
  Director
• Angelo William Jr Lovallo,
  Vice President Finance
• Hagop Youssoufian,
  Executive Vice President R&D
• Capital, L.P.Altiva Managem...,
  
• Heinz Christoph Maeusli,
  Director
• Gerard Ber,
  Director
• Ann L. Mac Dougall,
  Director
• Eric J Ende,
  Director
• Vivien Wong,
  EVP, Development
• David W. Mims,
  Interim CEO and Interim CFO
• Bryce Tenbarge,
  SVP, Commercial
• Benedict Osorio,
  COO
• Asha Das,
  Chief Medical Officer